{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003879","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.590338+00:00","generated_at":"2026-06-07T02:30:10.173384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Royalty Pharma expects 2023 Portfolio Receipts of ~$3.05B, exceeding upper guidance; 11% underlying growth","bullets":["Portfolio Receipts for FY2023 expected ~$3.05B, above prior guidance of $2.95B-$3.0B; underlying growth 11% YoY.","Net cash from operations for FY2023 ~$2.98B-$2.99B.","Announced transactions since 2020 total ~$13B, including $4.0B in 2023; synthetic royalty transactions at record $775M.","Capital deployment target of $10B-$12B from 2022-2026; longer-term potential to double annual deployment to $4B-$5B.","Portfolio investments since 2020 expected to add ~$1.2B to Portfolio Receipts in 2025 based on consensus sales forecasts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003879","json":"https://secwatch.observer/filing/0001193125-24-003879.json","markdown":"https://secwatch.observer/filing/0001193125-24-003879.md","text":"https://secwatch.observer/filing/0001193125-24-003879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524003879/0001193125-24-003879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524003879/d910834d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:30:10.173384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}